Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.42 |
| ▸ | TEK | Q02763 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721386 | 0.90 | SCN9A (0.52) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL1721618 | 0.84 | SCN9A (0.47) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL29575907 | 0.84 | SCN9A (0.47) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL23582507 | 0.82 | SCN9A (0.52) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL12170346 | 0.81 | SCN9A (0.48) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL1721390 | 0.81 | SCN9A (0.54) | SCN9AEPHB4TEKKDRADORA3 | |
| SCHEMBL31357667 | 0.81 | SCN9A (0.48) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL31357713 | 0.81 | SCN9A (0.48) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL23582835 | 0.81 | SCN9A (0.48) | SCN9ACYP17A1EPHB4TEKKDR | |
| SCHEMBL1721714 | 0.80 | SCN9A (0.47) | SCN9ACYP17A1EPHB4TEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160143898-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-26 | — | — | US | disclosed |
| US-9216969-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| US-8741933-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130237568-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| US-20130237569-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| US-8461156-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318733-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-20110312958-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 823/4885CYP17A1 3137/4885RAB9A 2011/4885 |
| US-20130237569-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 823/4885CYP17A1 3137/4885RAB9A 2011/4885 |
| US-20160143898-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | SCN9A 823/4885CYP17A1 3137/4885RAB9A 2011/4885 |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20110312958-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20130237568-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SCN9A 696/4885CYP17A1 3352/4885RAB9A 2101/4885 |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | SCN9A 823/4885CYP17A1 3137/4885RAB9A 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.